plasma
Review
Plasma Medicine: A Brief Introduction
Mounir Laroussi Electrical & Computer Engineering Department, Old Dominion University, Norfolk, VA 23529, USA; mlarouss@odu.edu; Tel.: +757-683-6369
Received: 28 January 2018; Accepted: 17 February 2018; Published: 19 February 2018
Abstract: This mini review is to introduce the readers of Plasma to the field of plasma medicine. This is a multidisciplinary field of research at the intersection of physics, engineering, biology and medicine. Plasma medicine is only about two decades old, but the research community active in this emerging field has grown tremendously in the last few years. Today, research is being conducted on a number of applications including wound healing and cancer treatment. Although a lot of knowledge has been created and our understanding of the fundamental mechanisms that play important roles in the interaction between low temperature plasma and biological cells and tissues has greatly expanded, much remains to be done to get a thorough and detailed picture of all the physical and biochemical processes that enter into play.
Keywords: low temperature plasma; plasma jet; cells; tissue; apoptosis; cancer; wound healing; reactive species

1. Introduction
In the mid-1990s, experiments were conducted that showed that low temperature atmospheric pressure plasmas (LTP) can be used to inactivate bacteria [1]. Based on these results, the Physics and Electronics Directorate of the US Air Force Office of Scientific Research (AFOSR) funded a proof of principle research program in 1997 and supported such research for a number of years. The results from this research program were widely disseminated in the literature, including in peer-reviewed journals and conference proceedings, therefore attracting the attention of the plasma physics community to new and emerging applications of low temperature plasma in biology and medicine [2­8]. The goals of the AFOSR program were to apply low temperature plasmas (LTP) to treat the wounds of injured soldiers and to sterilize/disinfect both biotic and abiotic surfaces. By the early 2000s, research expanded to include eukaryotic cells when small doses of LTP were found to enhance phagocytosis, accelerate the proliferation of fibroblasts, detach mammalian cells without causing necrosis, and under some conditions, lead to apoptosis [9,10].
The above-described groundbreaking research efforts showed that nonthermal plasma can gently interact with biological cells (prokaryotes and eukaryotes) to induce certain desired outcomes. These early achievements raised great interest and paved the way for many laboratories from around the world to investigate the biomedical applications of LTP and by the end of the first decade of the 2000s, a global scientific community was established around such research activities. The field is today known by the term plasma medicine, and in the last few years a number of extensive reviews and tutorials were published (see Refs [11­18] and references therein) as well as a few books [19­21].
Today, the field of plasma medicine encompasses several applications of low temperature plasmas in biology and medicine [22­53]. These include:
- Sterilization, disinfection, and decontamination, - plasma-aided wound healing

Plasma 2018, 1, 47­60; doi:10.3390/plasma1010005

www.mdpi.com/journal/plasma

Plasma 2018, 1

48

- plasma dentistry

-Plasmaca20n1c8e, r1,a5pplications or "plasma oncology,"

2 of 14

---

plasma pharmacology, pcalanscmeraatprepalticmaetinotnosfoirm"ppllaanstms afoornbcioolcoogmyp,"atibility. plasma pharmacology,

- Ipnlathsme laattere2a0t0m0se,nsteovfeirmalpLlTanPtssofuorrcbesiowcoemrepaaptpibriolivteyd. for cosmetic and medical use. Examples are:

in 200I8ntthheeUlaSteFD20A00asp,psreovveerdalthLeTPRhsyotuerccPesorwtreariet®a(ppplarsomveadjefto)rfocrosumseeitnicdaenrdmmatoedloigcay.l Auslseo. EinxathmepUleSs

oatrhee: rinpl2a0s0m8athdeevUiSceFsDaAre ainppursoevteoddathyefoRrhvyatercioPuosrmtraeidt®ica(lpalapspmliacajetito)nfos,rsuuscehinasdtehremBaotvolioegJ-yP. lAaslsmoai®n

atnhde tUhSe CotahneardpylaHsmeliaosdCevoilcdesPlaarsemina aunsde HtoydbaryidfoPrlavsamriaoTuMs Smcaeldpiecal.lIanpGpelircmataionny,s,thseucmheadsictahledBevoivciee

cJe-Prtliafiscmatai®onacnldassthIeIaCwaansadgyiveHnetloiotshCe oklIdNPPelans®m(aplaansdmaHjyebt)riidn 2P0l1a3sm, aanTdM tShcealPpleals.mInaDGeerrmm®andye,vitchee

(mCIeNdiOcaGlYdGevmicbeHc)ewrtaifsicaaltsioonapcplarossveIdIa. Fwigausreg1iviesna ttoimtehleinekIgNraPpehn®sho(pwlainsmg athejemt) aijnor2m01il3e,staonndestihne

tPhleasdmevaeDloeprmm®endt eovf itchee(fiCeIlNdOoGf lYowGtmembHpe) rwatausrealpsolasampparmoveeddic. iFnieg.ure 1 is a timeline graph showing

the major milestones in the development of the field of low temperature plasma medicine.

FFiigguurree11.. Timeline showing ssoommee mmaajjoorrmmiilleessttoonneessooffththeennewewfifieledldofotfhtehebiboimomedeidcaiclaalpapplpiclaictiaotniosnosf olof wlowtemtepmepraetruarteuraetmatomspohsperhicerpicrepsrseusrseuprelapsmlaasm. Tah.isThtiims etilmineldinoeesdnoeost snhootwshtohwe ctahsee coafsteheorfmthaelr(mhoatl) (phloats)mpalass, mwahsi,cwh hwicehreweurseedusfeodr fomramnyandyedcaedcaeds eisninmmedeidciaclalaapppplilciactaitoionns srreeqquuiririningg hheeaatt,, ssuucchh aass ccaauutteerriizzaattiioonnaannddbbllooooddccooaagguullaattiioonn..
22.. LLTTPPTTaakkeessoonnHHyyggieienneeaannddMMeeddicicaal lCChhaallelennggeess
AAssccaannbbeesseeeennffrroommFFiigguurree11tthheebbiioommeeddiiccaallaapppplliiccaattiioonnss ooffLLTTPPssttaarrtteeddwwiitthheexxppeerriimmeennttssoonn tthhee iinnaaccttiivvaattiioonnooffbbaacctteerriiaaoonnbbiioottiiccaannddaabbiioottiiccssuurrffaacceessaannddmmeeddiiaa.. BBaacctteerriiaall ccoonnttaammiinnaattiioonn pprroovveedd ttooppoosseesseevveerreecchhaallleennggeessffoorrssoommeeiinndduussttrriieessaannddiinntthheehheeaaltlthhccaarreeaarreennaa..TThheeiinndduussttrriiaallcchhaallleennggeess aarreemmaaiinnllyyaarroouunnddtthheepprroobblleemmoofffofoooddccoonntatammininaattioionnaannddssteterriliilzizaattiioonnoofffofoooddppaacckkaagginingg..SSeevveerraall wweelll--ppuubblliicciizzeedd ffoooodd ppooiissoonniinngg iinncciiddeennttss ((EEHHEECC,, LLiisstteerriiaa,, SSaallmmoonneellllaa)) ppooiinntteedd oouutt ttooccoonnssuummeerrss tthhaatt tthhee present methhooddss eemmppllooyyeeddbbyyththeefofoododinidnudsutrsytrmy amyanyotnboet badeeaqdueaqtue atoteintosuirnesuforoedfosoafdetsya.fTethye. Thheealhtheacaltrhecacrheacllheanlgleensgaersealrienkliendketdo tnoonsoscoocmomialiailnifnefcetciotinosnscacuausesdedbbyyaannttiibbiioottiicc rresistant strains ooff bbaacctteerriiaa,, ssuucchhaassMMeetthhiicciilllliinn--rreessiissttaanntt SSttaapphhyyllooccooccccus aureus ((MMRSA) and CClloosstridium diffificile (C--diff). EEvveerryyyeyaerairn tihne tUhSe, hUoSsp, ithaol sapciqtualireadcqinufiercetdionisnf(eHcAtioI)nksill(HthAouI)saknidlls othf opuatsiaenndtsswoitfh pcoamtiepnrtosmwiseitdh icmompurnoemsiyssetdemims.mHunAeI sayrsetecmaus.seHdAbIyairneadcaeuqsueadtebsyteirnilaizdaetqiounat/edestceorniltiazmatinonat/idoencoonftainmsitnruatmioenntos,f siunrsftarucems,encltos,thsiunrgf,acbeesd, schleoetthsi,nagn, dbepdesrhsoeentnse, la(nndurpsesrsaonndnedl o(cntours)e.s Iannmd odsot cctaosres)s., cInonmtaomsitncaatisoens, bcyonstaramininsaotfiobnacbtyersitararienssisotaf nbtatcotetrhiae rbeessitstaannttibtoiotthicembeesdtiacnatiobinostiacvmaieladbicleattiodnasyavisaitlhaeblceautosdeaoyf iHs AthIe. LcTaPusies othfeHreAfoIr. eLcToPnsisidtehreerdefaosrea cnoonvseildteercehdnaosloagynothvaetl cteacnhbneolsougcycetshsafut lclaynapbeplsiuedccteosshfeullplysoalpvpeliseodmteo ohfetlhpescohlvaellesnogmees odfetshcreibchedallaebnogvees. described above.
The most recent application presently receiving much attention is the use of LTP to destroy cancer cells and tumors in a selective manner [38­58]. Starting around the mid-2000s several investigators reported experiments showing that low temperature plasmas (LTP) can destroy cancerous cells in vitro. This was followed by some in vivo work showing that LTP can reduce the size of cancer tumors in animal models. The in vitro work covered a host of cancerous cell lines,

Plasma 2018, 1

49

The most recent application presently receiving much attention is the use of LTP to destroy cancer cells and tumors in a selective manner [38­58]. Starting around the mid-2000s several investigators reported experiments showing that low temperature plasmas (LTP) can destroy cancerous cells in vitro. This was followed by some in vivo work showing that LTP can reduce the size of cancer tumors in animal models. The in vitro work covered a host of cancerous cell lines, which included glioblastoma, melanoma, papilloma, carcinoma, colorectal cancer, ovarian cancer, prostate cancer cells, squamous cell carcinoma, leukemia, and lung cancer. The in vivo (animal model) work can be found in [38,44,45,53].
In addition to direct plasma applications to cancer cells and tissues, investigators reported that plasma-activated media (PAM) can also be used to destroy cancer cells [38,50,54­58]. Plasma-activated medium is produced by exposing a biological liquid medium to LTP for a length of time (minutes). In this case, the plasma-generated reactive species interact with the contents of the medium and generate solvated long-lived reactive species in the liquid, such as hydrogen peroxide, H2O2, nitrite, NO2-, nitrate, NO3-, peroxynitrite. ONOO-, and organic radicals. These molecules subsequently react with the cells and tissues causing various biological outcomes.
3. Mechanisms of Biological Action of LTP: Brief Summary
Investigators reported that the effects of LTP on biological cells (prokaryotes and eukaryotes) are mediated by reactive oxygen and nitrogen species (RONS) [11,12,59­66]. These species include hydroxyl, OH, atomic oxygen, O, singlet delta oxygen, O2(1), superoxide, O2-, hydrogen peroxide, H2O2, and nitric oxide, NO. For example, the hydroxyl radical is known to cause the peroxidation of unsaturated fatty acids, which make up the lipids constituting the cell membrane. The biological effects of hydrogen peroxide are mediated by its strong oxidative properties affecting lipids, proteins, and DNA (single and possibly double-strand breaks). Nitric oxide, which acts as an intracellular messenger and regulator in biological functions, is known to affect the regulation of immune deficiencies, cell proliferation, induction of phagocytosis, regulation of collagen synthesis, and angiogenesis.
In cancer cells, the mechanisms of action of LTP are suspected to be related to an increase of intracellular reactive oxygen species (ROS), which can lead to cell cycle arrest at the S-phase, DNA double-strand breaks, and induction of apoptosis. Research by various groups showed that RONS generated by LTP react with cell membranes and can even penetrate the cells and induce subsequent reactions within the cells that can trigger cell-signaling cascades, which can ultimately lead to apoptosis in cancer cells [56­66]. In addition, investigators have shown that plasma-generated RONS can indeed penetrate biological tissues up to depths of more than 1 mm and therefore interact not only with the cells on the surface but with those underneath [67­72].
LTP delivers not only reactive species but it also can exhibit large enough electric fields [73­77]. The magnitudes of these electric fields are several kV/cm and they are suspected to play a role, such as in cellular electroporation, which may allow large molecules to enter the cells.
4. Two LTP Sources for Biomedical Applications: Brief Description
The main LTP devices used in plasma medicine research are the dielectric barrier discharge (DBD) and nonequilibrium atmospheric pressure plasma jets (N-APPJ). In fact, the DBD was the device used in the first experiments on the inactivation of bacteria [1]. The DBD uses plate electrodes covered by a dielectric (such as glass). The plasma is generated in the gap separating the electrodes by the application of high sinusoidal voltages in the kHz frequency range. Gases such helium with admixtures of oxygen or air are usually used. For more information on the working of the DBD see references [61,78,79]. Figure 2 shows a schematic of the DBD and a photograph of a diffuse plasma at atmospheric pressure generated by a DBD.

Plasma 2018, 1 PPllaassmmaa22001188,,11,,55

50 44ooff1144

((aa))

((bb))

FFFiiiggguuurrreee22.2.S.cSShccehhmeeammtiacat(tiaicc) a((lnleedfftat))paahnnodtdogaarappphhhoo(tbtoo)ggorrfaaappnhhatomoffoasanpnhaeatrtmimc oposrseppshshueerrreiiccdipfpfrureessessspuulraresemddaiiffgffueunsseeerapptelladassbmmyaaa
dielectric barrier discharge (DBD). The discharge in the photo on the right is driven by kHz sinusoidal
ghgeiegnnheevrraoatltteeaddgebbayynada tddhieieelgleeacscttirrsiichcebblaiaurrmrriieewrridtdhiisasccshhmaararglgleead((DmDBiBxDDtu))r..eTTohhf eaeidrd. iiPsschchohtaaorrgtgaeekeiinnnatththteehpephahuootthtoooroo'nsnltathbheoerrariitggohrhytt. iiss ddrriivveenn bbyy kkHHzz ssiinnuussooiiddaall hhiigghh vvoollttaaggee aanndd tthhee ggaass iiss hheelliiuumm wwiitthh aa ssmmaallll aaddmmiixxttuurree ooff
aNaiiror..nPPehhqoouttoiolitbtaarkkiueenmnaatatttthmheeoaasupuththheoorrir'c'sslplaarbbeosorsrauatrtooerryyp..lasma jets (N-APPJs) produce plasma plumes that
propNaNgooannteeeqqauuwiilliaibbyrrifiuruommmaatthtmmeoocssoppnhhfieenrrieiccmppernreetsssosufurreeelepcptllaraossmdmeaas ajjeenttsds (i(nNNt-o-AAtPhPPePJJass)m) pbprireoonddtuuaccieer. ppTllahasesmmraeaapcptlliuuvmemesespsetcthhiaeatst pgpreronoppearaaggtaaettdee baawywtaahyyeffprroloammsmtthaheecaccnoonnthffiiennreemmfoeernenttsoaoffeeleylleeacctntrrdooddceoesns vaanennddieiinnttoloyttbhheeetaramamnbbsipieeonnrtt eaadiirr.t.oTThahetearregeaaecctttiaivvteea srspepemeccoiieetses glgoeecnnaeetriraoatnteeddanbbdyytathhweeappyllaafsrsmommaactcahanentmthheaerireneffoporlreaesssmaaffaeellgyyeanannedrdacctoioonnnvveaenrneiieaenn. ttlTlyyhbibseecttrhraannrsaspcptooerrttieesdtdicttoomaaattdaarerggNeett-AaattPaaPrJresemmvoeotrteye lalootctcaraatticiootninveaantnoddoalaswwfaoayryaffprropommlictathhtieeonmmsaaiininnbppiollaalsosmgmyaaaggneednnemerraeatdtiioiocnninaaerre[e6aa0..,T8T0hh­iis8s2cc]hh. aVarraarccitoteeurrisisstptiicocwmmeaardddeeriNNv-i-nAAgPPmPPJJessthvvoeerdryys atahttttarratacicnttiicvvleuetdtooeoopllssufflosorerdaappDppClliic,caRattFiio,onansnsdiinnmbbiiiocolrlooogwgyyaavanenddpmomweededriicchiinnaeve[e[66b00,e,88e00n­­8u822s]e]..dVV.aaIrnriiooauudssdppitooiwownee,rrvddarriivvoiiunnsggemmleeectthhrooddses tcthhoaanttfiiignnucclrluaudtdieoenppsuurlalssneedgdinDDgCCf,r,oRRmFF,,saainngddlemmeilicecrrcootwrwoadavvee,etpopootwweoer-rrhihnaagvveelbebceeteernonduuesseedwd..rIaInpnpaaedddddiaittriioonun,n, vdvaatrhriioeouoususteesllieedccettrrwoodadelel cocoofnnafficiggyuulirrnaadttiriooincnassl rdraainenglgeiicnntgrgicffrrbooommdys,siitnnoggtllwee oeel-lereiccnttrgrooeddlee,c,tttroodttwewsooa--rtritinancggheeldleectctotrrocoeddneetssrawwllryraapppepreefdodraartroeoduundnddielttehhceetroiocuudttssiisiddkese whwaaavllleloobffeaaecncyyulliinsnedddrr.iiccFaaillgdduiiereellee3ccttsrrhiiccobwboosddypy,h,totootottwgwrooa--prrihinnsggoeeflletecwcttroroodNdee-sAsaaPtttPtaaJcsch,hetehddettopolccaeesnnmttrraaalplllyyenppceeirlrffoaonrradatteetdhdeddikieeIlNleeccPttrerinicc, dwdiishskikcsshhhhaaavvveeebbeeeenn uusseedd.e. FxFtiigegnuusrrieeve33lysshihnoowpwlsassppmhhaootmtoogegrdraaipcpihnhses oroeffstetwawroochNN. --AAPPPPJJss,, tthhee ppllaassmmaa ppeenncciill aanndd tthhee kINPen, which have been used extensively in plasma medicine research.

((aa))

((bb))

tFFttFhhhiiigegegeuuulplerrerlefeeaftts33i3mi.s..sPPtPathhhhhpeooeoettptonpoolgcglagairrsrlsaama(mppOpahhahDsspspUooeoeffn,fnttcNtcwwiwiloloo(or(OfpOpopDlllDalakaUssU,smmmV,,aNAaNaj,ojeojeeUrttrsftsfSsoottAlhtlhkhka)a,a,,ttUtaUhhnhSaSadvaAAvve)(e)e,bb,ba)ebaeneienesndedntnuhttuosueosestkedthehdIdeNieniirnPrnivigevgavnharhatir(toriIiiouiNsosusutPtshb,sheibGeboikirmokoeImINmieNfdsePePwiddceeianaicncllada(al(Il,pINaNaGpppPlPepip,rc,lmGlaiGictcraairaeotnetiiniifoyfosssn).wn.ws(s.aa.aTl)Tlddoios,, GGeerrmmaannyy)). . The plasma plumes emitted by N-APPJs turned out to be made of small plasma packets traveling
at veTrTyhheheigpphllaavssemmloaaciptpileluusmm(teesnsseeommf ikitttmteed/ds)bb.yyThNNe-s-AeAPpPPlPaJJsssmttauurprnnaecedkdetoosuucttamttooe btboeebmemakadndeoewoonffasssmm"apalllal sppmllaaassmbmuaallepptasa"cckkaeenttdss tttrhraaevvyeewlliinnegrgeaaitnt vdveerpryyenhhdiigeghnhtvlvyeelfiloorccsiittirieeessp(o(ttreetnensds oionff ktkhmme//mss)).i.dTT-h2h0ee0sse0esppbllayassTmmesaacphpakaceckkeeetttasslccaaanmmdeebtytooLbbueeakknnndooLwwanrnoauassss""ipp[l8laa3ss,m8m4aa]. bLbuuulllaleenttsds""Laaannrddoutthhseseiyyuwwseedrreeniiannnddoeesppeeecnondndedenn-pttlluyylfsfieirrdssttDrreCeppopororttweedderiinnwtthhieelemmTieidds-c-22h00k00e00sestbbayylTTuesesescdchhkRkeFeeepttoaawllaeanrn.ddTbhbyeyLpLuluaasamnndda LbLauarlroloeuutsssswii [e[88r3e3,,8s84u4]b]..sLLeuquuaaennnddtlyLLaarrerosoueuassrssciihuuessdeeddexnntaeannosoisvseeeccloyon,nbddo--ptphuulelssxeepddeDrDimCCeppnootwawleleyrrawwnhhdiillbeeyTTmeessoccdhhekkleeineegtt,aabllyuuvsseaedrdioRRuFFs pipnoovwweesertri..gTTahthoeerpspl[la8as5smm­9aa1]bb.uuTllolleedttsasywwteherreeeressuiusbbassegeqrqeuueeemnntetllnyytrrteehssaeetaatrrhccheheepddlaeesxmxtteeannbssiuivvleleellytys,, abbrooetthghueeixxdppeederriiimomneeinnztataatlillolyynaawnndadvbbeyys. mTmooolddeeaelrliinngga,b, bobyuytvvtahareriisooeuugssuiiinndvveeedsstitioiggnaaittzooarrtssio[[n8855w­­9a91v1]e]..sTTionoddgaaryeyattthehererrdeeeitisasiala,ggtrhreeeeemrmeeaendntetrtthihsaatrtetfthheerereppdllaatssomm[a9a2b]b.uulllleettss aarree gguuiiddeeddiioonniizzaattiioonn wwaavveess..TToo lleeaarrnn aabboouutt tthheessee gguuiiddeedd iioonniizzaattiioonn wwaavveess iinn ggrreeaatteerr ddeettaaiill,, tthhee rreeaaddeerr iiss rreeffeerrrreedd ttoo [[9922]]..

PPllaassmmaa 22001188,, 11,,55

55 ooff511144

55.. TTwwoo BBiioommeeddiiccaall AApppplliiccaattiioonnss ooff LLTTPP 5. Two Biomedical Applications of LTP
TToo iilllluussttrraattee tthhee eeffffeeccttss ooff LLTTPP oonn bbiioollooggiiccaall ttaarrggeettss,, ttwwoo aapppplliiccaattiioonnss aarree sshhoowwnn hheerree.. TThhee ffiirrsstt ccoonncceeTrronnsisltlthuhesetbrbaaatccetteetrhriiceciidedfaaflel pcptrrsoooppfeerLrttTyyPoofof LnLTTbPPioaalnondgditcthhaeletssaeerccgooenntdsd, ssthwhooowwasspttphhleeiceeaffftfeieoccnttsssooaffrdediisrrheecocttwppnllaahssmemraea.eeTxxphpoeossfiuurrrseet acasosnwwceeerlllnl asassthppellabasasmmctaearaiacccittdiivavalatpteerddopmmereetddyiiaoafooLnnTPccaaannnccdeerrtohouuessseaacnnoddndhheseahaloltthwhyys etehppeiittehhfefeelliciaatlsl coceeflldllssi.r. eTTchhteeplrraeesssmuulalttssexppprroeessseuennretteeadds bwbeeellololwwasaaprreleabsbmaassaeeddacootinnvatthhteeeduumsseeeodofifatthhoene ppclalaansscmmeraaopupesennaccniidll ddheeessacclrrtihibbyeededpeeiatahrrleliileeirar..lTTchehleelsrr.eeTssuhuellttsrsessshhuooltwws nnprwweseeerrneetoeodbbttbaaeiinnloeewdd babyryettbhhaeesaeapdpppolliniccatahttiieoonunsooeffotthfhetehLLeTTpPPlappslmluumampeeeggneecnnileedrraaettseecddribbbyeydtthheeaerpplilleaarss.mmTahaeppereennsccuiillltoosnnshaaobbwaanccttewerreiiaarlel lloaabwwtanninsseeeededdbeeyddtoohnne tathhpeeplssiucuarrtffiaaoccneeooofffthaae PLPTeetPtrriipdlduiismshhe (g(sseeeneeerFFaiitggeuudrrebey44t))h..eTTphhleeasbmbaaaccttpeeerriniuucmmil ouunssaeeddbawcwtaeasrsiaAAl clcaiinnweetntoobsbaeacectdteeerrdccaoallnccootaahcceeettsiiuccuursfsa,,caae gogrfraaammP--ennteergigadattiisivvhee(sssoeoieillFbbiaagccuttereerriiu4u)mm. Taahllsesoobfafoocuutennrddiuiimnn ttuhhseeetdtiiggweerarsmmAoocssiqqnueutiiottoboa,,cwwtehhriicccahhlciiossakckenntoiocwwusnn, tatoogbbreaemaa-ttnrraeangnsasmtmiviisessssiioooninl vbveaeccctttoeorrriuoomff yyaeelsllloloowfwouaannndddinddteehnneggtuuigeeefrfeemvveeorrsssq..uFFiitigogu,uwrreehi55chsshhisookwwnssowzzoonnnteeossbooeffaiintnraaaccnttsiivmvaaittsiisooinnon((ddvaearcrktkorcciiorrfccuyulelaalrlroawarreeaaanssd)) adarreoonuugnnudde tfthehveeeccresen.ntFteeirgruoorffetth5heeshddoiiswshhswwzohhneeerrseeotthfheienpapcllataissvmmataaioppnlluu(dmmaeerkwwcaiarsscuaaplpapprllaiieerdeda..sTT)hhaeeroppuhhnoodttoothtteoocttehhneetellereffottfiistshffeoordr iaasnhn Ii1wIintnt0ihi9titiei/sisaarmlelccbbLltlaehae,acacewtrtrepehrrlttiiiahahlaseaacmcttotohannttahchpcteeeelnounntkmtkrriaiatlelhtltliiiiweononngngraisogoeefahfffp1ft1fe0ep0ic9sc9l/t/itmsfmesodllra,a.,rwarwTeenhhheiimimlnlepeoiothttrirhhaeoeaalttotceeoooxtxnonntteectttnnhehhddneeeeterlrrddeiiaggftthhiaaoitntnsnididsfsooffrofpopra1rrron0aoan7nnni/onoiimuniuntniniiLtatcici.aleaeIlbdldtcacioocsffntnooeccrcrrleeeinanatththrtcrreeoatahnttilialcooootenwnwnthoetoerfrefra11kti0ii0nion7l7/iln/imtimtiniaoalgll.fl. cecooffnneccceetsnntatrrraaettiimoonno..rFeFooerrxmtmenoordreeediinnaffoonrrdmmpaarttoiioonnnouoonnncttehhdeefddoeerpptehenneddleoenwncceeerooifnf iiintniaaacclttciivovanattciieoonnntrooanntittohhnee.ppFlloaarssmmmaaoreeexxpipnoofssouurrmreeattitimimoene aoannnddthooenndtthehpeeettnyydppeeenoocffebboaafccittneearriciaat,i,vtthahteeiorrneeaaoddneertrhiises rpreelfafeesrrmrreeaddetxtoop[o[99s33u]]r..e time and on the type of bacteria, the reader is referred to [93].

FFFiiiggguuurrreee 444... EEExxxpppeeerrriiimmmeeennntttaaalllssseeetttuuupppfffooorrr ttthhheee bbbaaacccttteeerrriiiaaalll iiinnnaaaccctttiiivvvaaatttiiiooonnn eeexxxpppeeerrriiimmmeeennntttsss...

cFFLcFoioiiegnggnfutucucerperreneenictt5rtr55.uaa..tKrtieiKoiKolnilniisil.ln.llfiLigLnonergepgff1trto0ppppp9rri/ioecocrmtptputueyeLrrrreoettayyfinisLsdoToffofPofrrir:gLLD11hTT00etP9Pp9/p/:m:emincDDlltduaeaeerpnpnnededecniensrdrdoifigegoefnhnhrthctct1eeep0pk7iioco/citlftfmluuinrtrtLheghe.eeieiBssfakfikffciocioltlarlerlicirn1ny1ig0ug0o77m/n/memeftfiflhsfli.i.cecABaBai.acnacyccyicatttieleaocrorloininuabucammettchthtieieceissuriAsiaAin.n.c.iLitcotcTiainaaalPllcclcoeosbanbaocactauerecctrattitcietcecieurouriisinasas... LtLhTTePPpssloaousumrrccaeepiissetnthhceeilppollpaasesmrmaataeppdeewnncciitilhl oohppeeelriruaatmteeddawswaiitthchahrhreeileliiurumgmasaass[9aa3c]c.aarrrriieerr ggaass [[9933]]..
FFiigguurree 66 sshhoowwss tthhee eeffffeeccttss ooff ddiirreecctt aapppplliiccaattiioonn ooff LLTTPP oonn ssuussppeennssiioonnss ooff ccaanncceerroouuss cceellllss.. TThhee coccoarearnilniglgcciileneniFrnraiagellccllueyeyurllsloeloebb6lldititnsanahweieinnoaeuweusddssseaefftddrrhsooqewmwmueaafaafasmsehhcaoautusumsmsosqqfaaucundneaailbmrbmlellcaocaoadtuduradsdcspeiencprcre.oel.ilAlmAcllaffcactttaieaeoorrrrncfcLLiitonTnThfooPPeLmmTebeaxaPxlappoodooonffdssuseutthurrhreesee(pSaabebCnnlnldaadasdBdippodEdrnreoReosrrpp,oeA(e(fSrSrcTCCiianCnanaccCBcBuueEEbbHrRRoaaT,tu,tiiBsoAoAn-cnT3TepTCplClMrsrCCo.o)cTcoHeHehrssTeisTsgBcB((i3a3n--37n37aTcT lMMely)r) uounbndtdaeeirnr e55d%%fCrCoOOm22 aaattmmhuoomssppahhneerrbeel))a,,dTTdrryeyrpp.aaAnn-f-btbellurueeLTeexxPccleluuxsspiiooonsnuaarssessaaayyndwwpaasrsouupsseeerdditntoocuccobouauntnitot ntthhpeernnouucmemsbsbee(r3r 7ooff°lCliivvueenaadnneddr d5d%eeaaddCOccee2llllass.t.mFFooorrsdpdehetteaariiells)s,ooTffrtythhpeeaeenxx-pbpeleurrieimmeeexnnctltauallspiporrnoottaoosccsooallyppwlleeaaassseeurrseeeffdeerrtottooc[o[44u00n]]..tTTthhheee cncoouuumnnbttsseirimmomfmleievddeiiaaatteneldlyydaafefttaeedrr LLTTPP ttrreeaattmmeenntt ((aatt 00 hh)) rreevveeaalleedd nnoo ddeeaadd cceellllss,, wwhhiicchh ssuuggggeesstteedd tthheerree wweerree nnoo iimmmmeeddiiaattee pphhyyssiiccaall

Plasma 2018, 1

52

cells.PFlaosmrad20e1t8a, i1l,s5 of the experimental protocol please refer to [40]. The counts immediately6aofft1e4r LTP

treatment (at 0 h) revealed no dead cells, which suggested there were no immediate physical effects.

Plasma 2018, 1, 5

6 of 14

Howeefvfeecrt,st.hHeovwieavbeirl,ittyheovficaeblilistyreodf uceclelsdretoduacreodutnodar5o0u%nda5t02%4aht 2a4ftherafate2r-am2i-nmiLnTLPTtPretraetamtmeennt.t.AAs seen

in Figesfuefeernectis6n.,HhFioggwuhereevre6pr,,lhtahisgemhveairaebpxillapitsoymsoaufreceexlptlisomsrueedrseurcteiemsduetlsot rianersomuulntodirne5m0c%eolrlasetkc2ei4llhesdakfit(le5ler-dma (2i5n--mmpiinlnaLspmTlPaastmrtreaeaattmrtemeantemtn. etAnrstesults
in 75s%reeesonuflitlnsoiFsnsig7ou5f%revoi6af,blhoiislgisthyoefravtpial2ab4simlhitaypeaoxtsp2t-o4tsrhuepraeotmstitm-etnreetsa)rt[me4s0eun]l.tt)Tin[h4m0e]s.oeTrerheecsseuelllsrtesksiulnlletdsdiicn(a5dt-iemcatihnteaptthlaLasTtmLPaTdPtrodeeaostemns oenntottapply immeraedpsipualltytesibimnrmu75tee%dpioahfteylosbsircsuaotlfefvopirahcbyeislioictnyalatfhtoe2r4cceheloplsno,stbth-uetrteciaettlslmse,efbfneutc)tt[si4t0sre]e.qfTfuheicertseselroreenqsguueilrtrsebilnoiodnligoceagrtiecbatiholaltotimgLiTceaPsltdtoiomesshesonwotot. This is anasiphnpodwliyc.aiTmtihomisneidtshiaaatnte pibnlrdauistcmeatpaiohanygsteihcnaattlspf,olsarucsemchoanaasgthereenatcsce,tlsilsvu,ecbhsupatseitcrsieeaesfcftaeivncteds srepeleqecuciteirrseicalnofidnegledelresc,btiirnoictloefgrieaiclcdatlsw,tiiminttheesrtahtcoet cells acanndciewsdwdnhreeidioatcathwhutethhlct.tlhheosoTefefrhhtcetciohheseaeulelclilsrscstcsiaaaaaonnnlnnnaccddesteienririanrndcc.nddeiecdlululalsc/scteiehohororroneeuuatatrrrchcsisttgaiillotoagantntpeeesslrrraa.a.bsnnmiddoa//cooharrgettmerriniggitgcgse,aerlsrubpbciiaohotcchhahwseemmraeiyiaccscaatlltivhppeaaatttshhpuwweltcaaiiyymesssattahhtneaadlttyuuelrlltteeiicmsmturaailtctteeliflyniyerlrtdeehssseu,ulildtnteitinenarttathhhceetof the

FigurFeig6u. rVeia6b.ilVitiyaboifliStyCaoBfESRCcaeBlElsRincemllesdiina tmreeadtieadtdreiraetcetdlydbiryetchtleyLbTyP tphleumLTePofptlhuempelaosfmtahepencil reveaFplildgaeusamrdea(6bp.leaVnccikailbbrialerivtsyeoanol fdtoSepaC)daaB(nbEdlRalcikvceebll(asgrrsienoennmbteoadpris)a)actnerdellaslt.ievTdeh(edgivrreieaecbntliylbitaybrysw) tacheselmlsL.oTnPhiteoprvleuidambaietli0toy,f1w2th,a2es4 and
48h ppmolsaotsn-mLitTaoPrpetedrneacatitlm0r,e1vn2et,a[24l40d]ae.nad 4(b8lhacpkosbta-LrsToPntrteoapt)maenndt l[i4v0e].(green bars) cells. The viability was
mFiognuirteor7edshaot w0,s12th, e24saenledct4iv8eh pefofsetc-tLTofP LtrTePatmwehnetn[4it0]c. omes to destroying cancer cells versus
FhiegaultFrhieyg7ucreselhlso7 winshsvotiwhtreso.stehTleheecstevilvieaecbteiivlfifeteycertfefoescuftlLtosTfPshLwoTwPhnewnihnitetnchoeimtficegosumrteoesbdeteolsotwdroewsytirenorgye iconabgntacciaennrecdceerullscsienvllges rpvsluearssmuhsaealthy cellshainectaivlvtihatrtyeodc.emTllhseedinivavi(aiPtbrAoilM.itT)y,hwreehvsiiucahlbtiswlistayhsorcerwesuantletisdnsbthhyoewexfinpgoiunsirntehgbebefiliogoluowgreiwcbael rlloieqwoubiwdtaemrineedeodibatuatoisnitenhdegpuplslaianssmgmapalpaeasnmcctailvated mediafaoctr(iPvcAaetrMetad)in,mwleedhniigacthh(PswAoaMfst)ic,mrweeha. itTcehhdewbcayasneccxreepraootuesdisncbgeylbleilxoinploegsuiinscegadlbliwioqlauosgidSicCamalBleiEdqRuiaidatnomdtehtdheieaphtloaeasthlmtehayp/plnaeosnmrmcailaplfeocnreclclislertain lengtfwhosreroceefrMtiamDinCelK.eTn(ghMtehascdaionnf-cDteimarroebu.ysTchcaenlilcnaleinnckeidruonsueesyd)cecwlellallssinfSerCoumasBendEoRwrmasanldSeCptahitBehEehRleiaallnttdihsystuh/eenoohfermaaltdaholygc/nekloildrsmnweayel .rceTelhMlse DCK (Madwmineer-dDeiaMaruDbsyeCdKctao(nMminaadekiknei-PdDAnaMrebyy)wcceaernlelisnMefErkoMimd(nmneyoin)rimcmealullsmefrpeosimtshenenltoiiaarmll mtailsesedupiaeit)hofeoflriaaSldCtoiasgBsuEkeRidoanfneadyd.EoaTgghlkeeidMmnieendyim.iaTuhumesed to makemEPsesAdeinMatiuawsleMedreetdoMimaE(aEMkMe (EPmMAiMn) fiomwreuMrmeDMCesEKsM.eFni(tgmiauilrnemim7eusdhmioawe)sfssoetrhneStiCraelasmBulEetdsRi[a5a)7nf]od. rESaCgalBeEMR iannidmEuamgleEMssiennimtiaulmMedia (EMEEMsse)nfotiralMMDedCiaK(.EFMigEuMre) f7osrhMoDwCsKth. Feigreusruel7tssh[5o7w].s the results [57].

Figure 7. Viability in percent of SCaBER (cancerous) and MDCK cells (noncancerous) treated by

Ffoigr uvPFrMPaeiArAgTi7MuoMS.rueVafsfsooi7sarlra.ebvyvnViaalgairirantitioybhoduiusilTsinstoryllypefepnnietngiargmncttpheh-ebesns.rltoucoVfeoefnitfteaitimSxmbocCieelflu.a.iStsVBVyiCEoiiaaawnRbbBiaiaEl(lsicsiRtstayyaany(swwccsa[ea5eanrs7ssco]saea.uesrsdossse)uesasasssf)neetddeadnraMad1fftt2DeMerrhCD11oK22CuhKhcroseoucluilernrslsslc(siuninn(obcncunauobtcbniaaaoctntaniionconecwnerworwitouihiuttshhs)P)PAtPrtAAreMeMaMattueeuuddsssiiibnnbnyggyg

PAM MTS

assayMaTnSdaTssrayypaannd-bTlruyepeanx-cbluluseioenxcalusssiaoyn[a5s7s]a.y [57].

Plasma 2018, 1

53

Figure 7 shows that PAM created using longer exposures to LTP has increasing killing effects on SCaBER cancer cells, reducing their viability to below 10% for irradiation times longer than 2 min. However, normal MDCK cells were able to withstand exposure to PAM for 3 min. This illustrates the selectivity of PAM in killing cancer cells while sparing healthy cells. But for PAM created with longer exposures to LTP (6 minutes and more) extensive killing of MDCK cells was obtained. This illustrates that the plasma dose is an important factor to take into consideration for optimal outcomes.
6. Penetration of RONS in Tissues
One of the key questions in plasma medicine is the following: Do the RONS generated by LTP only interact and affect cells on the surface of a tissue (or tumor) or do they penetrate the tissue and affect cells in deeper layers? Experimental evidence has shown that LTP does indeed affect cells underneath the tissue surface but what remains unclear is how. One possible explanation is what is referred to as the "bystander effect," which implies that there are chemical signals sent by the cells on the surface (in contact with plasma) to cells in the layer below [41]. These signals would trigger reactions similar to those occurring at the cells on the surface, including the onset of apoptosis. However, and to the best of this author's knowledge, there has been no experimental proof this occurs when LTP interacts with tissues. So, the possibility is there, but reliable data that can be replicated needs to emerge first. Therefore, in this section, only experiments that reported qualitatively and/or quantitatively on the penetration of RONS are presented.
In order to qualitatively and quantitatively elucidate RONS penetration into tissues, investigators used various in vitro models. Oh et al. investigated the penetration of RONS using a model made of an agarose film covering a volume of deionized water contained in a quartz cuvette [67]. They found that RONS kept being delivered from the agarose film to deionized water underneath it for up to 25 min after the plasma was removed. To study the delivery of reactive oxygen species (ROS) into cells, Hong et al. used a model comprising phospholipids vesicles encapsulated within a gelatin matrix and equipped with reactive oxygen species (ROS) reporter [68]. They found that ROS were delivered to the cells without rupturing the membranes of the vesicles. To simulate biological tissue, Szili et al. used gelatin gel, a derivative of collagen, and reported on the penetration behavior of H2O2 through a 1.5 mm thickness gelatin film [69]. The same authors also investigated the effects on DNA in synthetic tissue fluids, tissue, and cells [94].
Tissue models are useful and provide preliminary data regarding the penetration of RONS through biological targets. However, to simulate more realistic conditions, Duan et al. used slices of pig muscle tissue of different thicknesses placed on top of a PBS solution [72]. Figure 8 shows the experimental setup. A plasma jet operated with a helium/oxygen mixture was used. To ignite the plasma sinusoidal high voltages at a frequency of 1 kHz were employed. The plasma treatment times were 0, 5, 10, and 15 min.

Plasma 2018, 1 Plasma 2018, 1, 5

54 8 of 14

FFiigguurree88. .EExpxepreimriemnetanltsaeltuspetuuspinugspiniggmpuisgclme tuisssculee [t7i2s]s.uReep[7ro2d].uRceedpfrroodmuDceudanf,rJo.;mLuD, uXa.;na,nJd.; LHue,,
XG..; Pahnyds.HPel,aGsm. aPsh2y0s1. 7P,la2s4m, 0as732500167,, w24i,th07th35e0p6e, rwmitishsitohne poferAmIPissPiuobnliosfhAinIgP. Publishing.
differTTehhneet ccthooninccckeennnettsrrasaettisioononfsstoohffeHHti22sOOs2u,2e,OOsHliH,cea,.naAdndtchotahmtapot faortfihsteohnetototoaftlatohlfeos(fNe(ONco2On- c2+e-Nn+tOraN3t-)iOown3-ser)wewhmeeerneasnmuoreetaidsssufuoreerd for wdiaffseuresnetdtahnicdknwehsesnesaotfistshueetiwssausepsllaicceed. Aoncotomppoafritshoensoolfutthioenseschoonwceednttrhaatitotnhsewcohnecnenntorattisiosnuse was oo5fuatFuh0nfrisgni0edOcug-cdk3tHrr,niaeemoO2eann9Os-tdHtessoh2r.hw,fiwHocatthkiwinesoserdsstnsweuiustHaemeehsvu2tetoOietheshmsri2st,csiulcewklmyikeancenscoeweruoer.seenrsasFesmsstiad.ughpnoumaHcldsanorteoeclnfdyw8esocd0re9cbe%notvyohstnenhrrtorsaheoft,uteoewitmmophptsineelosoasdtsrf(hsueNomtbeehfyOtame(ahN2tntsaeh-roOdnaeelsa+2uctu8-toitmNsr0iuoes+%elOudndnNe3stcon-Ohaotfoi)non3mtwdtp-chpeee)eceansndaoste(ssu(r5ttNaalhr,tdtha1aOiftor0utneo2n,tn-oduhasct+gneatopihdcof5Naon501s(nON0s05oc0-3tOfmeµ--hµ)ntm2rii-mtsnoprs-+uuateuohttgnNeierihoecstOgtn)kh5r.rs3ai0e-tct)oi0akes-ftasndesOuermesaa3ts,issOalsinucHdee,. for three plasma treatment times (5, 10, and 15 min).

Plasma 2018, 1 Plasma 2018, 1, 5

55 9 of 14

Figure 9. Total nitrite and nitrate concentration versus tissue thickness for three plasma exposure Ftiimguesre[792. ].ToRteapl rnoidtruitceedanfdronmitrDatueacno, nJ.c;eLnutr,aXti.o; nanvderHsues, tGis.sPuheytsh. iPcklansmesassf2o0r1t7h,r2e4e,p0l7a3s5m0a6,ewxpitohsuthree tpimermesis[7si2o]n. RofeAprIoPdPuucbeldisfhrionmg Duan, J.; Lu, X.; and He, G. Phys. Plasmas 2017, 24, 073506, with the permission of AIP Publishing.
Figure 9 shows that the concentrations of the nitrogen reactive species, RNS, decrease with the tissueFitghuicrken9esshs,obwust tinhcartetahseecwonitchetnhteraptiloasnms aoftrtehaetmnietrnotgteimn ere. aTchteivceosnpceecnitersa,tRioNnSo,fd(NecOre2a- s+eNwOit3h-)tfhoer ttihsesu5e00th-icmknteissssu, ebuthtiicnkcnreeasssewwasithcotmhepparlaasbmleatotrtehaetmcoennctetnimtrea.tiTohnewchonencennotrtaitsisouneowf a(Ns pOl2a-ce+d NonOt3o-p) foofrtthheeP5B00S-µsomluttiisosnu.eTthhiicskmneesasnws aths actom(RpNaSra)bwleetroe tahbelecotoncpeenntreattriaotne wthheetnisnsouetisssliucee.wTahsisplwacaesdnoont ttohpe ocafstehefoPrBRSOsoSl,uwtihoinc.hTwhiesremaebasnosrtbheadt (bRyNthS)ewtiesrseuea,bulentloikpeetnheetrcaatseethwehteinssuaegselliactei.nTmhiosdwelas(nnoottrtehael ctiassseufeo)rwRaOsSu,swedh.icFhorwtehraetambsoodreble,dRbOyStwheertiessaubele, utonlpikeenethtreacteastehewgheelnataingefillamti.n model (not real tissue) was uTsheed.abFoovr etheaxtammopdleesl,iRlluOsStrwateertehaabtlRe OtoNpSendeotrnaottestihmepgleylarteiancfit wlmit.h the surface of tissues but can indeeTdhepeanbeotvreateexraemlaptilveesliylludseterpaltye.tHhaotwReOvNerS, idnomnoortesirmeaplliystirceaccotnwdiittihonthseussuinrfgacaectoufatlistsisuseuseb, uittwcaans isnhdoewend tpheantentroattealrleRlaOtiNveSlycadneecprolys.sHthoewseavmeer, tihnicmkonreessr.eSaloimstiec ccaonndbietiaobnssourbsiendgwacitthuianl atisfseuwe,tietnws aosf smhiocwronmtehtaetrsnboyt athlleRtOissNuSe,cwanhiclreoostshtehres csaanmpeetnheictrkanteesus.pStoom1.e5 cmanmbbeealobwsotrhbeedsuwrfiatchei.nOaffceowurtseen,sthoef mabiocvroemreetseurlstsbymtahye tniosstuceo,mwphlieleteolythreerfsleccatnwpheantetwraoteuludphtaop1p.5enmumndbeerloiwn tvhievosucrofancdei.tiOonfsc.oSuursceh, tehxepearbimoveentrsesnueletds mtoabyencoont dcoumctpedleatenldy croemflepcatrwedhatot rweosuulltds ohbatpapineendufnordienr vinitrvoivmoocdoenlds iatniodntso. tShuocshe eoxbptaeirnimedenutnsdneereedxtvoivbeo ccoonndduitciotends a[9n5d].compared to results obtained for in vitro models and to those obtained under ex vivo conditions [95].
7. Conclusion 7. Conclusions
To conclude this brief introduction of the field of plasma medicine, it is safe to say that the biomTeodiccoanl claupdpelitchaitsiobnrsiefoifntrloodwucttieomnpoefrathtuerefielpdlaosfmpalashmaavemeodpiceinneed, ituips saafne toenstairyeltyhatntehwe bmioumltieddiisccaipl alipnpalriycatfiioenlds oofflorweseteamrcpherraetquureirpinlagsmclaosheavceoollpaebnoeradtiuopnanbeetnwtiereenly pnhewysimciustltsi,diesncgipinlienearrsy, fibieoldloogfisrtess, ebairocchheremqiustirsi,nagndclomseedcioclalal beoxrpaetriotsn. Tbehtiws meeunltpidhiyssciicpislitnsa, reyngfiienledersst,abrtieodloignismtsi,db-i1o9c9h0esmwisittsh, asenmd imnaeldiecxapl eerxipmeerntst.s Tohnis tmheulitnidaicstciivpaltiinoanryofif ebldacsttearritaedbyinlmowid-t1e9m90pserwaittuhreseamtminoaslpehxepreircimperenstssuorne tphleasimnaactgivenateiroanteodf bbaycatedriiaelbeyctlroicwbtaermrieprerdaitsucrhearagtme aonspdhselroiwc plyreesxspuarendpeladsmtoaingcelnuedreatiendvebsytiagadtiieolnecstroinc beuarkraieryrodtiiscchcealrlgs.eAanpdplsicloawtiolynsexinpadnedremdattooliongcylu, dweoiunnvdeshtiegaaltiinogn,sdoennteiustkrayr,yaontdic ccaenllcse. rAhpapvleicaletidontos ivnardioerums astcoielongtiyf,icwaoduvnadncheesalainngd, dtoentthiestriyd,eaantdhacat nLcTePr hcaavne bleedatotevcahrniooulosgsyciuenptoifincwadhivcahncveasriaonuds tinontohveaitdiveea thmaetdLicTaPl ctahnerbaepaietsecchannolobgeyduepvoenlowpehdichtovaorvioeurcsoimnneovparteisveenmt ehdeiaclatlhcthaererapciheasllceanngebse. dHeovweleovpeerd, atolootvreermcoaminesptroesbeentdhoenaeltihncaorredcehr atlolefnuglleys.uHnodweresvtaenr,da tlhoet rmemecahinans itsombseodfoancetiionnoordf eLrTtPo fauglalyinustnbdieorlsotgaincdaltcheellms aencdhatnisissumess,obfoathctiionnvoitfroLTaPndaginaivnisvtob. iTohloegreiciaslscterollnsganinddtiicsastuioens,tbhoatthLiTnPvaitcrtos asenldecitnivveilvyoo. nThcearneceisr scterollns ganinddtiucamtioorns tahnadt LcTaPn apcetnsesterlaetcetidveeelyp obnelcoawnctehrecseullrsfaacned, tbuumt omrus cahndmcoarne pweonrekt,rainteclduedeipngbeelxotwentshiveesuclrifnaiccea,lbturitamls,uicshnmeeodreedwboerfko,riencLlTuPdicnagnebxetecnosnivseidcelirneidcaal tsraifaelst,eicshnneoeldoegdy
ready for use in hospitals to treat chronic wounds, cancer lesions and tumors, and other ailments.
Conflict of Interest: The author declares no conflicts of interest.

Plasma 2018, 1

56

before LTP can be considered a safe technology ready for use in hospitals to treat chronic wounds, cancer lesions and tumors, and other ailments.
Conflicts of Interest: The author declares no conflicts of interest.
References
1. Laroussi, M. Sterilization of Contaminated Matter with an Atmospheric Pressure Plasma. IEEE Trans. Plasma Sci. 1996, 24, 1188. [CrossRef]
2. Garate, E.; Evans, K.; Gornostaeva, O.; Alexeff, I.; Kang, W.; Rader, M.; Wood, T. Atmospheric plasma induced sterilization and chemical neutralization. In Proceedings of the IEEE International Conference on Plasma Science, Raleigh, NC, USA, 1­4 June 1998. [CrossRef]
3. Laroussi, M.; Sayler, G.; Galscock, B.; McCurdy, B.; Pearce, M.; Bright, N.; Malott, C. Images of biological samples undergoing sterilization by a glow discharge at atmospheric pressure. IEEE Trans. Plasma Sci. 1999, 27, 34. [CrossRef]
4. Hermann, H.W.; Henins, I.; Park, J.; Selwyn, G.S. Decontamination of chemical and biological warfare (CBW) agents using an atmospheric pressure plasma jet (APPJ). Phys. Plasmas 1999, 6, 2284. [CrossRef]
5. Birmingham, J.G.; Hammerstrom, D.J. Bacterial decontamination using ambient pressure nonthermal discharges. IEEE Trans. Plasma Sci. 2000, 28, 51. [CrossRef]
6. Laroussi, M.; Alexeff, I.; Kang, W. Biological Decontamination by Non-thermal Plasma. IEEE Trans. Plasma Sci. 2000, 28, 184. [CrossRef]
7. Montie, T.C.; Kelly-Wintenberg, K.; Roth, J.R. An overview of research using the one atmosphere uniform glow discharge plasma (OAUGDP) for sterilization of surfaces and materials. IEEE Trans. Plasma Sci. 2000, 28, 41. [CrossRef]
8. Laroussi, M.; Richardson, J.P.; Dobbs, F.C. Effects of Non-Equilibrium Atmospheric Pressure Plasmas on the Heterotrophic Pathways of Bacteria and on their Cell Morphology. Appl. Phys. Lett. 2002, 81, 772. [CrossRef]
9. Shekhter, A.B.; Kabisov, R.K.; Pekshev, A.V.; Kozlov, N.P.; Perov, Y.L. Experimental and Clinical Validation of Plasmadynamic Therapy of Wounds with Nitric Oxide. Bull. Exp. Biol. Med. 1998, 126, 829. [CrossRef]
10. Stoffels, E.; Flikweert, A.J.; Stoffels, W.W.; Kroesen, G.M.W. Plasma Needle: A non-destructive Atmospheric Plasma Source for Fine Surface Treatment of Biomaterials. Plasma Sources. Sci. Technol. 2002, 11, 383. [CrossRef]
11. Fridman, G.; Friedman, G.; Gutsol, A.; Shekhter, A.B.; Vasilets, V.N.; Fridman, A. Applied plasma medicine. Plasma Process. Polym. 2008, 5, 503. [CrossRef]
12. Laroussi, M. Low Temperature Plasmas for Medicine. IEEE Trans. Plasma Sci. 2009, 37, 714. [CrossRef] 13. Barekzi, N.; Laroussi, M. Effects of Low Temperature Plasmas on Cancer Cells. Plasma Process. Polym. 2013,
10, 1039. [CrossRef] 14. Keidar, M.; Shashurin, A.; Volotskova, O.; Stepp, M.A.; Srinivasan, P.; Sandler, A.; Trink, B. Cold atmospheric
plasma in cancer therapy. Phys. Plasmas 2013, 20, 057101. [CrossRef] 15. Laroussi, M.; Mohades, S.; Barekzi, N. Killing of Adherent and non-adherent Cancer Cells by the Plasma
Pencil. Biointerphases 2015, 10, 029410. [CrossRef] 16. Laroussi, M. Non-Thermal Decontamination of Biological Media by Atmospheric Pressure Plasmas: Review,
Analysis, and Prospects. IEEE Trans. Plasma Sci. 2002, 30, 1409. [CrossRef] 17. Laroussi, M. Low Temperature Plasma-Based Sterilization: Overview and State-of-the-Art.
Plasma Proc. Polym. 2005, 2, 391. [CrossRef] 18. Von Woedtke, T.; Reuter, S.; Masur, K.; Weltmann, K.-D. Plasma for Medicine. Phys. Rep. 2013, 530, 291.
[CrossRef] 19. Laroussi, M.; Kong, M.; Morfill, G.; Stolz, W. Plasma Medicine: Applications of Low Temperature Gas Plasmas in
Medicine and Biology; Cambridge University Press: Cambridge, UK, 2012; ISBN 978-1-107-00643-0. 20. Fridman, A.; Friedman, G. Plasma Medicine; Wiley: New York, NY, USA, 2013; ISBN 978-0-470-68970-7. 21. Keidar, M.; Beilis, I.I. Plasma Engineering: Applications from Aerospace to Bio and Nanotechnology; Academic
Press: London, UK, 2013; ISBN 978-0-12-385977-8.

Plasma 2018, 1

57

22. Laroussi, M. Interaction of Low Temperature Plasma with Prokaryotic and Eukaryotic cells. In Proceedings of the 61st Gaseous Electronics Conference, Dallas, TX, USA, 13­17 October 2008; American Physical Society: Ridge, NY, USA; p. 29.
23. Isbary, G.; Morfill, G.; Schmidt, H.U.; Georgi, M.; Ramrath, K.; Heinlin, J. A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. Br. J. Dermatol. 2010, 163, 78. [CrossRef] [PubMed]
24. Morris, A.D.; McCombs, G.B.; Akan, T.; Hynes, W.; Laroussi, M.; Tolle, S.L. Cold Plasma Technology: Bactericidal Effects on Geobacillus Stearothermophilus and Bacillus Cereus Microorganisms. J. Dental Hygiene 2009, 83, 55.
25. Claiborne, D.; McCombs, G.B.; Lemaster, M.; Akman, M.A.; Laroussi, M. Low Temperature Atmospheric Pressure Plasma Enhanced Tooth Whitening: The Next Generation Technology. Int. J. Dent. Hygiene 2013. [CrossRef] [PubMed]
26. Laroussi, M.; Barekzi, N. Effects of Low Temperature Plasma on Two Eukaryotic Cell Lines: Epithelial Cells and Prostate Cancer Cells. In Proceedings of the 31st ICPIG, Granada, Spain, 14­19 July 2013.
27. Barekzi, N.; Laroussi, M. Fibropblasts Cell Morphology Altered by Low Temperature Atmospheric Pressure Plasma. IEEE Trans. Plasma Sci. 2014, 42, 2738. [CrossRef]
28. Laroussi, M.; Karakas, E.; Hynes, W. Influence of Cell Type, Initial Concentration, and Medium on the Inactivation Efficiency of Low Temperature Plasma. IEEE Trans. Plasma Sci. 2011, 39, 2960. [CrossRef]
29. Fridman, G.; Brooks, A.; Galasubramanian, M.; Fridman, A.; Gutsol, A.; Vasilets, V.; Ayan, H.; Friedman, G. Comparison of direct and indirect effects of non-thermal atmospheric-pressure plasma on bacteria. Plasma Process. Polym. 2007, 4, 370. [CrossRef]
30. Shashurin, A.; Keidar, M.; Bronnikov, S.; Jurjus, R.A.; Stepp, M.A. Living tissue under treatment of cold plasma atmospheric jet. Appl. Phys. Lett. 2008, 93, 181501. [CrossRef]
31. Laroussi, M.; VanWay, L.; Mohades, S.; Barekzi, N. Images of SCaBER Cells Treated by Low Temperature Plasma. IEEE Trans. Plasma Sci. 2014, 42, 2468. [CrossRef]
32. Xiong, Z.; Cao, Y.; Lu, X.; Du, T. Plasmas in tooth root canal. IEEE Trans. Plasma Sci. 2011, 39, 2968. [CrossRef] 33. Zimmermann, J.L.; Shimizu, T.; Boxhammer, V.; Morfill, G.E. Disinfection through different textiles using
low-temperature atmospheric pressure plasma. Plasma Process. Polym. 2012, 9, 792. [CrossRef] 34. Babaeva, N.; Kushner, M.J. Reactive fluxes delivered by dielectric barrier discharge filaments to slightly
wounded skin. J. Phys. D: Appl. Phys. 2013, 46, 025401. [CrossRef] 35. Weltmann, K.-D.; Kindel, E.; Brandenburg, R.; Meyer, C.; Bussiahn, C.; Wilke, C.; von Woedtke, T.
Atmospheric Pressure Plasma Jet for Medical Therapy: Plasma Parameters and Risk Estimation. Contrib. Plasma Plasma Phys. 2009, 49, 631. [CrossRef] 36. Ehlbeck, J.; Schnabel, U.; Polak, M.; Winter, J.; von Woedtke, T.; Brandenburg, R.; von dem Hagen, T.; Weltmann, K.-D. Low temperature atmospheric pressure plasma sources for microbial decontamination. J. Phys. D Appl. Phys. 2011, 44, 013002. [CrossRef] 37. McCombs, G.B.; Darby, M.; Laroussi, M. "Dental Applications". In Plasma Medicine: Applications of Low Temperature Gas Plasmas in Medicine and Biology; Laroussi, M., Kong, M., Morfill, G., Stolz, W., Eds.; Cambridge University Press: Cambridge, UK, 2012. 38. Utsumi, F.; Kjiyama, H.; Nakamura, K.; Tanaka, H.; Mizuno, M.; Ishikawa, K.; Kondo, H.; Kano, H.; Hori, M.; Kikkawa, F. Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo. PLoS ONE 2013, 8, e81576. [CrossRef] [PubMed] 39. Tanaka, H.; Mizuno, M.; Ishikawa, K.; Takeda, K.; Nakamura, K.; Utsumi, F.; Kajiyama, H.; Kano, H.; Okazaki, Y.; Toyokuni, S.; et al. Plasma Medical Science for Cancer Therapy: Toward Cancer Therapy Using Nonthermal Atmospheric Pressure Plasma. IEEE Trans. Plasma Sci. 2014, 42, 3760. [CrossRef] 40. Mohades, S.; Barekzi, N.; Laroussi, M. Efficacy of Low Temperature Plasma against SCaBER Cancer Cells. Plasma Process. Polym. 2014, 11, 1150. [CrossRef] 41. Laroussi, M. From Killing Bacteria to Destroying Cancer Cells: Twenty Years of Plasma Medicine. Plasma Process. Polym. 2014, 11, 1138. [CrossRef] 42. Köritzer, J.; Boxhammer, V.; Schäfer, A.; Shimizu, T.; Klämpfl, T.G.; Li, Y.-F.; Welz, C.; Schwenk-Zieger, F.; Morfill, G.E.; Zimmermann, J.L.; et al. Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. PLos ONE 2013, 8, e64498.

Plasma 2018, 1

58

43. Schlegel, J.; Koritzer, J.; Boxhammer, V. Plasma in Cancer Treatment. Clin. Plasma Med. 2013, 1, 2. [CrossRef] 44. Vandamme, M.; Robert, E.; Pesnele, S.; Barbosa, E.; Dozias, S.; Sobilo, J.; Lerondel, S.; Le Pape, A.;
Pouvesle, J.-M. Antitumor Effects of Plasma Treatment on U87 Glioma Xenografts: Preliminary Results. Plasma Process. Polym. 2010, 7, 264. [CrossRef] 45. Keidar, M.; Walk, R.; Shashurin, A.; Srinivasan, P.; Sandler, A.; Dasgupta, S.; Ravi, R.; Guerrero-Preston, R.; Trink, B. Cold Plasma Selectivity and the Possibility of a Paradigm Shift in Cancer Therapy. Br. J. Cancer. 2011, 105, 1295. [CrossRef] [PubMed] 46. Laroussi, M.; Keidar, M. Plasma & Cancer. Plasma Process. Polym. 2014, 11, 1118. 47. Fridman, G.; Shereshevsky, A.; Jost, M.M.; Brooks, A.D.; Fridman, A.; Gutsol, A.; Vasilets, V.; Friedman, G. Floating electrode dielectric barrier discharge plasma in air promoting apoptotic behavior in melanoma skin cancer cell lines. Plasma Chem. Plasma Process. 2007, 27, 163. [CrossRef] 48. Volotskova, O.; Hawley, T.S.; Stepp, M.A.; Keidar, M. Targeting the cancer cell cycle by cold atmospheric plasma. Sci Rep. UK 2012, 2. [CrossRef] [PubMed] 49. Kim, C.-H.; Bahn, J.H.; Lee, S-H.; Kim, G.-Y.; Jun, S.-I.; Lee, K.; Baek, S.J. Induction of cell growth arrest by atmospheric non-thermal plasma in colorectal cancer cells. J. Biotechnol. 2010, 150, 530. [CrossRef] [PubMed] 50. Tanaka, H.; Mizuno, M.; Ishikawa, K.; Nakamura, K.; Kajiyama, H.; Kano, H.; Kikkawa, F.; Hori, M. Plasma activated medium selectively kills glioblastoma brain tumor cells by down-regulating a survival signaling molecule, AKT kinase. Plasma Med. 2013, 1, 265. [CrossRef] 51. Barekzi, N.; Laroussi, M. Dose-dependent killing of leukemia cells by low-temperature plasma. J. Phys. D Appl. Phys. 2012, 45, 422002. [CrossRef] 52. Huang, J.; Li, H.; Chen, W.; Lu, G.-H.; Wang, X.-Q.; Zhang, G.-P.; Ostrikov, K.; Wang, P.-Y.; Yang, S.-Z. Dielectric barrier discharge plasma in Ar/O2 promoting apoptosis behavior in A549 cancer cells. Appl. Phys. Lett. 2011, 99, 253701. [CrossRef] 53. Kim, Y.; Ballato, J.; Foy, P.; Hawkins, T.; Wei, Y.; Li, J.; Kim, S.O. Apoptosis of lung carcinoma cells induced by a flexible optical fiber-based cold microplasma. Biosens. Bioelectron. 2011, 28, 333. [CrossRef] [PubMed] 54. Tanaka, H.; Mizuno, M.; Ishikawa, K.; Nakamura, K.; Utsumi, F.; Kajiyama, H.; Kano, H.; Maruyama, S.; Kikkawa, F.; Hori, M. Cell survival and proliferation signaling pathways are downregulated by plasma activated medium in glioblastoma brain tumor cells. Plasma Med. 2012, 2, 207. [CrossRef] 55. Tanaka, H.; Mizuno, M.; Kikkawa, F.; Hori, M. Interactions between a plasma-activated medium and cancer cells. Plasma Med. 2016, 6, 101. [CrossRef] 56. Mohades, S.; Laroussi, M.; Sears, J.; Barekzi, N.; Razavi, H. Evaluation of the Effects of a Plasma Activated Medium on Cancer Cells. Phys. Plasmas 2015, 22, 122001. [CrossRef] 57. Mohades, S.; Barekzi, N.; Razavi, H.; Maramuthu, V.; Laroussi, M. Temporal Evaluation of Antitumor Efficiency of Plasma Activated Media. Plasma Process. Polym. 2016, 13, 1206. [CrossRef] 58. Mohades, S.; Laroussi, M.; Maruthamuthu, V. Moderate Plasma Activated Media Supresses Proliferation and Migration of MDCK Epithelial Cells. J. Phys. D Appl. Phys. 2017, 50, 185205. [CrossRef] 59. Graves, D. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J. Phys. D Appl. Phys. 2012, 45, 263001. [CrossRef] 60. Lu, X.; Naidis, G.V.; Laroussi, M.; Reuter, S.; Graves, D.B.; Ostrikov, K. Reactive Species in Non-equilibrium Atmospheric Pressure Plasma: Generation, Transport, and Biological Effects. Phys. Rep. 2016, 630, 1. [CrossRef] 61. Laroussi, M.; Lu, X.; Keidar, M. Perspective: The Physics, Diagnostics, and Applications of Atmospheric Pressure Low Temperature Plasma Sources Used in Plasma Medicine. J. Appl. Phys. 2017, 122, 020901. [CrossRef] 62. Zhao, S.; Xiong, Z.; Mao, X.; Meng, D.; Lei, Q.; Li, Y.; Deng, P.; Chen, M.; Tu, M.; Lu, X.; et al. Atmospheric Pressure Room Temperature Plasma Jets Facilitate Oxidative and Nitrative Stress and Lead to Endoplasmic Reticulum Stress Dependent Apoptosis in HepG2 Cells. PLOS ONE 2013, 8, e73665. [CrossRef] [PubMed] 63. Yan, X.; Zou, F.; Zhao, S.; Lu, X.; He, G.; Xiong, Z.; Xiong, Q.; Zhao, Q.; Deng, P.; Huang, J.; et al. On the Mechanism of Plasma Inducing Cell Apoptosis. IEEE Trans. Plasma Sci. 2010, 38, 2451. [CrossRef] 64. Yan, X.; Xiong, Z.; Zou, F.; Zhao, S.; Lu, X.; Yang, G.; He, G.; Ostrikov, K. Plasma-Induced Death of HepG2 Cancer Cells: Intracellular Effects of Reactive Species. Plasma Process. Polym. 2012, 9, 59. [CrossRef] 65. Ishaq, M.; Evans, M.; Ostrikov, K. Effects of Atmospheric gas Plasmas on Cancer Cell Signaling. Int. J. Cancer 2014, 134, 1517. [CrossRef] [PubMed]

Plasma 2018, 1

59

66. Ishaq, M.; Kumar, S.; Varinli, H.; Han, Z.J.; Rider, A.E.; Evans, M.; Murphy, A.B.; Ostrokov, K. Atmospheric Gas Plasma-Induced ROS Production Activates TNS-ASK1 Pathway for the Induction of Melanoma Cancer Cell Apoptosis. Mol. Biol. Cells 2014, 25, 1523. [CrossRef] [PubMed]
67. Oh, J.-S.; Szili, E.J.; Gaur, N.; Hong, S.-H.; Futura, H.; Kurita, H.; Mizuno, A.; Hatta, A.; Short, R.D. How to assess the plasma delivery of RONS into tissue fluid and tissue. J. Phys. D Appl. Phys. 2016, 49, 304005. [CrossRef]
68. Hong, S.-H.; Szili, E.J.; Toby, A.; Jenkins, A.; Short, R.D. Ionized gas (plasma) delivery of reactive oxygen species (ROS) into artificial cells. J. Phys. D Appl. Phys. 2014, 47, 362001. [CrossRef]
69. Szili, E.J.; Bradley, J.W.; Short, R.D. A `tissue model' to study the plasma delivery of reactive oxygen species. J. Phys. D Appl. Phys. 2014, 47, 152002. [CrossRef]
70. Gaur, N.; Szili, E.J.; Oh, J.; Hong, S.; Michelmore, A.; Graves, D.B.; Hatta, A.; Short, R.D. Combined effect of protein and oxygen on reactive oxygen and nitrogen species in the plasma treatment of tissue. Appl. Phys. Lett. 2015, 107, 103703. [CrossRef]
71. He, T.; Liu, D.; Xu, H.; Liu, Z.; Xu, D.; Li, D.; Li, Q.; Rong, M.; Kong, M. A `tissue model' to study the barrier effects of living tissues on the reactive species generated by surface air discharge. J. Phys. D Appl. Phys. 2016, 49, 205204. [CrossRef]
72. Duan, J.; Lu, X.; He, G. On the penetration depth of reactive oxygen and nitrogen species generated by a plasma jet through real biological tissue. Phys. Plasmas 2017, 24, 073506. [CrossRef]
73. Begum, A.; Laroussi, M.; Pervez, M.R. Atmospheric Pressure helium/air plasma Jet: Breakdown Processes and Propagation Phenomenon. AIP Adv. 2013, 3, 062117. [CrossRef]
74. Sobota, A.; Guaitella, O.; Garcia-Caurel, E. Experimentally obtained values of electric field of an atmospheric pressure plasma jet impinging on a dielectric surface. J. Phys. D Appl. Phys. 2013, 46, 372001. [CrossRef]
75. Stretenovic, G.B.; Krstic, I.B.; Kovacevic, V.V.; Obradovic, A.M.; Kuraica, M.M. Spatio-temporally resolved electric field measurements in helium plasma jet. J. Phys. D Appl. Phys. 2014, 47, 102001. [CrossRef]
76. Lu, Y.; Wu, S.; Cheng, W.; Lu, X. Electric field measurements in an atmospheric-pressure microplasma jet using Stark polarization emission spectroscopy of helium atom. Eur. Phys. J. Spec. Top. 2017, 226, 2979. [CrossRef]
77. Pervez, M.R.; Begum, A.; Laroussi, M. Plasma Based Sterilization: Overview and the Stepwise Inactivation Process of Microbial by Non-thermal Atmospheric Pressure Plasma Jet. Int. J. Eng. Technol. 2014, 14, 7.
78. Kogelschatz, U. Dielectric-Barrier Discharges: Their History, Discharge Physics, and Industrial Applications. Plasma Chem. Plasma Proc. 2003, 23, 1. [CrossRef]
79. Brandenburg, R. Dielectric barrier discharges: progress on plasma sources and on the understanding of regimes and single filaments. Plasma Sources Sci. Technol. 2017, 26, 053001. [CrossRef]
80. Laroussi, M.; Lu, X. Room Temperature Atmospheric Pressure Plasma Plume for Biomedical Applications. Appl. Phys. Lett. 2005, 87, 113902. [CrossRef]
81. Lu, X.; Laroussi, M.; Puech, V. On Atmospheric Pressure Non-equilibrium Plasma Jets and Plasma Bullets. Plasma Sources Sci. Technol. 2012, 21, 034005. [CrossRef]
82. Weltmann, K.-D.; Kindel, E.; von Woedtke, T.; Hähnel, M.; Stieber, M.; Brandenburg, R. Atmospheric-pressure plasma sources: Prospective tools for plasma medicine. Pure Appl. Chem. 2010, 82, 1223. [CrossRef]
83. Teschke, M.; Kedzierski, J.; Finantu-Dinu, E.G.; Korzec, D.; Engemann, J. High Speed Photographs of a Dielectric Barrier Atmospheric Pressure Plasma Jet. IEEE Trans. Plasma Sci. 2005, 33, 310. [CrossRef]
84. Lu, X.; Laroussi, M. Dynamics of an Atmospheric Pressure Plasma Plume Generated by Submicrosecond Voltage Pulses. J. Appl. Phys. 2006, 100, 063302. [CrossRef]
85. Mericam-Bourdet, N.; Laroussi, M.; Begum, A.; Karakas, E. Experimental Investigations of Plasma Bullets. J. Phys. D Appl. Phys. 2009, 42, 055207. [CrossRef]
86. Sands, B.L.; Ganguly, B.N.; Tachibana, K. A Streamer-like Atmospheric Pressure Plasma Jet. Appl. Phys. Lett. 2008, 92, 151503. [CrossRef]
87. Karakas, E.; Koklu, M.; Laroussi, M. Correlation between helium mole fraction and plasma bullet propagation in low temperature plasma jets. J. Phys. D Appl. Phys. 2010, 43, 155202. [CrossRef]
88. Boeuf, J.-P.; Yang, L.; Pitchford, L. Dynamics of guided streamer (plasma bullet) in a helium jet in air at atmospheric pressure. J. Phys. D Appl. Phys. 2013, 46, 015201. [CrossRef]
89. Naidis, G. Modeling of streamer propagation in atmospheric-pressure helium plasma jets. J. Phys. D Appl. Phys. 2010, 43, 402001. [CrossRef]

Plasma 2018, 1

60

90. Yousfi, M.; Eichwald, O.; Merbahi, N.; Jomma, N. Analysis of ionization wave dynamics in low-temperature plasma jets from fluid modeling supported by experimental investigations. Plasma Sources Sci. Technol. 2012, 21, 045003. [CrossRef]
91. Breden, D.; Miki, K.; Raja, L.L. Self-consistent 2D modeling of cold atmospheric-pressure plasma jets/bullets. Plasma Sources Sci. Technol. 2012, 21, 034011. [CrossRef]
92. Lu, X.; Naidis, G.; Laroussi, M.; Ostrikov, K. Guided Ionization Waves: Theory and Experiments. Phys. Rep. 2014, 540, 123. [CrossRef]
93. Laroussi, M. Low temperature plasma jet for biomedical applications: A review. IEEE Trans. Plasma Sci. 2015, 43, 703. [CrossRef]
94. Szili, E.J.; Gaur, N.; Hong, S.-H.; Kurita, H.; Oh, J.-S.; Ito, M.; Mizuno, A.; Hatta, A.; Cowin, A.J.; Graves, D.B.; et al. The assessment of cold atmospheric plasma treatment of DNA in synthetic models of tissue fluid, tissue and cells. J. Phys. D Appl. Phys. 2017, 50, 274001. [CrossRef]
95. Ray, A.; Ranieri, P.; Karamchand, L.; Yee, B.; Foster, J.; Kopleman, R. Real-Time Monitoring of Intracellular Chemical Changes in Response to Plasma Irradiation. Plasma Med. 2017, 7, 7. [CrossRef]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

